U.S. Online Retail and Ecommerce Stock News

Earlier this week, Compass Inc. formally dismissed its lawsuit against Zillow, ending the long-running “Zillow Ban” that had limited how listings could be marketed on Zillow’s platform and reshaping how agents and home sellers can promote properties. This resolution removes a key point of friction between Compass and a major listings portal, potentially clarifying Compass’s competitive positioning in an industry already wrestling with technology, regulation, and shifting brokerage...

Nebius Group, ticker NasdaqGS:NBIS, is reportedly in advanced talks to acquire Israeli AI startup AI21 Labs. The potential deal would mark a move beyond Nebius’s current focus on AI infrastructure into proprietary AI software and platform offerings. This M&A development has not featured in recent coverage that has centered on Nebius’s data center plans, analyst attention, and valuation scenarios. Nebius Group enters these reported talks with AI21 Labs after a period of very strong share...

What recent performance says about Cytokinetics Cytokinetics (CYTK) has drawn investor interest after a solid run in its share price, with the stock last closing at US$65.01 and showing large total returns over the past year and past 3 years. Over the past month, Cytokinetics has posted a return of 2.17%, with a 3.99% gain over the past 3 months and a 5.31% return year to date. Its 1 year total return of 68.20% and 3 year total return of 86.92% point to meaningful moves for longer term...

Wondering whether Pony AI at US$9.56 is starting to look interesting or still too expensive for the risk you would be taking. The stock has returned 3.7% over the last 7 days, while the 30 day return is a 25.9% decline and the year to date return is a 40.5% decline, set against an 80.4% return over the last year. Recent coverage has focused on Pony AI as a high growth, higher risk software name, with investors debating whether the sharp pullback in the last month is a pause after a strong 1...

Earlier in April 2026, Globus Medical was upgraded to a Zacks Rank #1 (Strong Buy) after analysts raised earnings estimates and signaled greater confidence in its outlook. This shift in analyst sentiment highlights how upward earnings revisions can materially influence perceptions of Globus Medical’s business quality and earnings power. Next, we’ll explore how this earnings-driven upgrade interacts with the existing investment narrative built around robotics innovation and acquisition...

In April 2026, Immunovant reported that two Phase 3 GO studies of its FcRn inhibitor batoclimab in adults with active, moderate-to-severe thyroid eye disease did not meet the pre-specified primary endpoint of ≥2mm proptosis response at Week 24, though safety findings remained consistent and no new signals emerged. The data suggested stronger proptosis improvements during the initial high-dose period and thyroid hormone normalization in hyperthyroid patients similar to prior Graves’ disease...

In recent days, Air Products and Chemicals reported quarterly results that exceeded analyst expectations and issued more optimistic full-year guidance, alongside increased holdings by several institutional investors. This combination of stronger earnings, upbeat outlook, and active institutional accumulation highlights growing confidence in the company’s execution across its core industrial gases and clean energy projects. Building on these earnings surprises and analyst upgrades, we’ll now...

Fresh attention on Coinbase Global (COIN) has been sparked by a wave of analyst coverage that questions the resilience of its fee model, trading volumes, and role in an increasingly institutional crypto market. See our latest analysis for Coinbase Global. At a share price of $167.85, Coinbase’s recent momentum has cooled, with a 30 day share price return of 15.5% lower and a 90 day return of 30.29% lower. However, the 3 year total shareholder return of 140.09% still indicates a very strong...

If you are wondering whether Kemper's current share price offers fair value or a potential discount, a good starting point is understanding how the market is pricing its risks and prospects today. The stock last closed at US$31.13, with returns of 1.7% over 7 days and 6.9% over 30 days, set against a 21.2% decline year to date and a 43.7% decline over 1 year. These moves sit against a backdrop of ongoing investor focus on Kemper's position within the insurance sector and on how its business...

Cooper Companies (COO) is drawing attention after its CooperVision unit launched the MADE BETTER Promise, a global sustainability platform initially tied to the MyDay daily disposable contact lens family. See our latest analysis for Cooper Companies. The share price is currently at US$71.21, with a 1-day share price return of a 0.35% decline and a 90-day share price return of a 14.67% decline. The 1-year total shareholder return of an 8.07% decline and 5-year total shareholder return of a...

In early April 2026, Salesforce filed a shelf registration for US$41.18 million of common stock linked to its employee stock ownership plan, while partners such as Solutions by Text and Redpanda expanded integrations that deepen Salesforce’s role at the center of compliant messaging and data streaming workflows. At the same time, investors are wrestling with whether Salesforce’s AI initiatives, like Agentforce and Slackbot, will offset competitive, pricing, and workflow-disruption risks that...

On 31 March 2026, Sineng Electric announced it will use onsemi’s latest-generation FS7 IGBT and EliteSiC hybrid power integrated modules in its 430 kW liquid-cooled energy storage systems and 320 kW utility-scale solar string inverters, targeting higher efficiency, power density and improved thermal performance in utility-scale renewable installations. Benchmark data suggest onsemi’s hybrid PIMs can lift inverter system efficiency by up to 0.1% and power-to-weight performance by 32%,...

Some investors may be wondering whether Chipotle Mexican Grill is starting to look attractively priced, or if the stock still has more heat baked into it than the fundamentals support. The share price closed at US$34.09, with recent returns of 2.8% over 7 days and 0.7% over 30 days, while the year-to-date move sits at a 9.1% decline and the 1-year return at a 31.5% decline, which may have some investors reassessing both risk and potential reward. Recent coverage has focused on how this...

Law firm opens investigation into potential fiduciary breaches by directors and officers of Estée Lauder Companies (NYSE:EL). Review focuses on whether management acted in the best interests of shareholders during recent corporate actions. Aerin Lauder and Ronald S. Lauder transfer large blocks of Class B shares into RSL Shares Trust, now a 10% beneficial owner. These developments occur while Estée Lauder is engaged in merger negotiations with Puig. Estée Lauder Companies, the beauty group...

On 9 April 2026, Tempus AI, Inc. announced an expanded multi-year collaboration giving Gilead Sciences enterprise-wide access to its AI-driven Lens platform and broader multimodal oncology datasets, alongside integrated Tempus analytical services. This deepened data and platform access positions Tempus more firmly inside Gilead’s oncology R&D workflows, embedding its technology in trial design, biomarker strategy, and real-world evidence generation across multiple cancer programs. We’ll now...

DuPont de Nemours (NYSE:DD) has introduced new water treatment technologies focused on industrial and municipal applications. The launch includes ultrafiltration modules with integrated pre filters and advanced reverse osmosis membrane elements. The products target resource recovery, regulatory compliance, operational efficiency and support for zero liquid discharge systems. For DuPont, water technologies sit alongside a broader portfolio that serves industrial, infrastructure and municipal...

Kiniksa Pharmaceuticals International (KNSA) is in focus after launching Heart’s Home, a multi-channel Direct-to-Consumer campaign for ARCALYST, its FDA-approved therapy for recurrent pericarditis. The initiative is aimed at raising awareness and prompting patient-provider conversations. See our latest analysis for Kiniksa Pharmaceuticals International. Despite a mild 1 day share price return of negative 0.53% and a 7 day share price return of negative 3.56%, Kiniksa’s 90 day share price...

If you are wondering whether Palantir Technologies at around US$128.06 is still priced for excitement or already ahead of itself, the starting point is to ask what you are actually paying for. The stock has seen a 13.7% decline over the last 7 days and a 16.6% decline over the last 30 days, even though the 1 year return sits at 44.6% and the 3 year return is very large. Recent coverage has focused on Palantir's role in data analytics and software platforms used by government and commercial...

Figma recently reported full-year 2025 revenue growth of 41% with solid free cash flow, while guiding 2026 growth to around 30% and remaining unprofitable. At the same time, investors are increasingly focused on how generative AI and intensified competition from Adobe could weaken Figma’s competitive position, even as user adoption remains strong. We’ll now examine how investor concerns about AI eroding Figma’s moat may influence the company’s existing investment narrative and risk...

Core & Main’s recent Q4 earnings report showed a 6.9% year-on-year revenue decline and slight misses on both quarterly revenue and full-year EBITDA guidance compared with analyst expectations. Despite these softer figures, investor reaction suggests the market may have been braced for weaker results or took confidence from management’s commentary and forward-looking remarks. We’ll now explore how the softer Q4 revenue and guidance miss may reshape Core & Main’s broader investment narrative...

If you are wondering whether United Airlines Holdings at about US$96.40 offers value or stretched expectations, it helps to look past the headline share price and focus on what that price implies. The stock has recently moved by 4.5% over the last 7 days and 6.3% over the last 30 days, with a 47.0% return over 1 year and a 131.3% return over 3 years, while the year to date return sits at a 14.7% decline and the 5 year return is 72.5%. Recent attention on United Airlines often centers on...

Analog Devices (ADI) is back in focus after semiconductor stocks rallied following easing U.S.-Iran tensions and the reopening of the Strait of Hormuz, while a major U.S. funding initiative targets chip supply chains. See our latest analysis for Analog Devices. Despite a 0.35% 1 day share price decline to US$350.14, Analog Devices has built strong momentum, with a 7 day share price return of 9.99% and a 1 year total shareholder return of 98.42%. This reflects how recent geopolitical easing,...

Netskope (NTSK), a Santa Clara based cybersecurity company, is drawing investor attention after recent trading left the stock around $8.67, with negative returns over the past month and the past 3 months. See our latest analysis for Netskope. The recent 30-day share price return of negative 28.52% and year-to-date share price return of negative 48.70% signal fading momentum, even though the stock posted a 1-day share price return of 2.36%. If you are comparing Netskope with other...

In recent days, Fair Isaac has come under intense political and regulatory pressure, with a Senate investigation into its credit score pricing practices and the Federal Housing Finance Agency urging more affordable access to credit scoring for mortgage borrowers. At the same time, concerns about growing competition in credit scoring and AI-enabled alternatives, alongside negative insider sentiment, have raised fresh questions about the resilience of Fair Isaac’s long-standing market...